Colgate-Palmolive Webcasts Presentation at the Barclays 2024 Global Consumer Staples Conference

NEW YORK--(BUSINESS WIRE)-- Colgate-Palmolive (NYSE: CL) Chairman, President and CEO, Noel Wallace, will present on Wednesday, September 4, 2024 at 10:30 a.m. ET at the Barclays 2024 Global Consumer Staples Conference.

Investors may access a live webcast of this presentation and the presentation slides on Colgate’s website at http://www.colgatepalmolive.com. For those unable to participate during the live webcast, a recorded version of the webcast will be made available through the Investor Center page of Colgate’s website.

* * *

Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom’s of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. We are recognized for our leadership and innovation in promoting sustainability and community wellbeing, including our achievements in decreasing plastic waste and promoting recyclability, saving water, conserving natural resources and improving children’s oral health through the Colgate Bright Smiles, Bright Futures program, which has reached approximately 1.7 billion children and their families since 1991. For more information about Colgate’s global business and how we are building a future to smile about, visit www.colgatepalmolive.com. CL-C

View source version on businesswire.com: https://www.businesswire.com/news/home/20240816827298/en/

Investor Relations: [email protected]
Communications: [email protected]

Source: Colgate-Palmolive

You May Also Be Interested In

• Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
• Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
• Best Crypto Presale 2026: Tesla-SpaceX Merger Talks Meet Remittix’s $33M Raise and November 24 Launch